Bal Pharma Limited · NSE:BALPHARMA
Bal Pharma — Q3 FY2023 Earnings Presentation
30 slides from Bal Pharma's earnings presentation, Feb 8, 2023
Slide 1: Exchange cover letter: Press Release and Investor Presentation
Bal Pharma Limited 08.02.2023 To, The Manager-Listing National Stock Exchange of India Ltd Mumbai. BSE Limited Mumbai. Dear Sir, Sub : Press Release and Investor Presentation. r presentation on the Unaudited We are submitting the attached press release and investo nine months ended 31.12.2022, finan
Slide 2: Press Release: Q3 & 9MFY23 results
Bal Pharma Limited PRESS RELEASE: BAL Pharma Limited showcased strong revenue growth for Q3 & 9MFY23 results against adverse market conditions. e Domestic Formulation witnesses robust growth of 42.74% in Q3FY23 and 30.27% in 9MFY23 e Revenue grows by 10.32% YoY to 773.35 million in Q3FY23 and 6.55%
Slide 3: Formulations and API business; management commentary
© Theshare of formulations in total revenue is 47.84% in Q3FY23 compared to 40.71% in Q3FY22. e In 9MFY23, domestic formulations stood at % 331.46 million compared to % 254.45 million in 9MEY22, registering a growth of 30.27%. Export formulations stood at % 792.47 million in 9MFY23 compared to % 583
Slide 4: About BAL Pharma Ltd (BPL)
About BAL Pharma Ltd (BPL) Bal Pharma Limited (BSE: 524824; NSE: BALPHARMA) is a fully integrated pharmaceuticals Company specialising in Bulk Actives, Prescription Drugs, Generics and pharma intermediates. Bal Pharma's focused therapeutic areas are Anti-diabetes, Anti-histamine, Anti-inflammatory,
Slide 5: Investor Presentation Q3 & 9MFY23
Slide 6: Disclaimer
Disclaimer This presentation and the following discussion may contain “forward-looking statements” by Bal Pharma Limited (“Bal Pharma” or the Company) that are not historical in nature. These forward-looking statements, which may include statements relating to future results of operations, financial
Slide 7: Contents
CONTENTS About Us Industry Integrated Play Financial Overview Leadership Team
Slide 8: About Us
ABOUT US COMMITTED TO QUALITY HEALTH CARE
Slide 9: A Leading Pharmaceuticals player focussed on treating lifestyle diseases
A Leading Pharmaceuticals player focussed on treating lifestyle diseases eS o Overview Vision Established in 1992, today the Company has a =" To be a leading global player in the Healthcare presence across more than 80 countries industry with a focus on innovation, quality, worldwide with strong Pan
Slide 10: 30 years of Legacy
30 years of Legacy Expanded its API’s portfolio to 20+ and FDF’s to 200+ gener vee? 2021 — 2011-2020 a= - 1996-2011 1992-1996 e Growth e The company increased its footprints across geography and Invest with expansion and integrated e The company started play, Company is on the growth I reaching vari
Slide 11: Bal Pharma at a Glance
Bal Pharma at a Glance First Indian company to be granted COS for First Indian Gliclazide & Largest company to file for producer Bepotastine in US &exporter of Gliclazide from feel yt fey India Exports : Domestic 7 a Intermediates, Finished . Formulations & 375 + field force and 3,138+ . ne distribu
Slide 12: Our State-of-the-Art Manufacturing facilities
Our State-of-the-Art Manufacturing facilities 6 manufacturing facilities- 3 for API’s & Intermediates , 3 for Finished Dosage Formulations (FDF) © Unit 1 — Bangalore, Karnataka © Unit 2- Bangalore, Karnataka Capacity © Unit 3- Pune, Maharashtra Unit 1 FDF 1.2 bn Tablets 240 mn Capsules © Unit 4- Rud
Slide 13: Our State-of-the-Art Manufacturing facilities
Our State-of-the-Art Manufacturing facilities API- Unit 2 Bangalore, Karnataka FDF- Unit 1, Bangalore, Karnataka
Slide 14: Diversified Global Markets
Diversified Global Markets Diversified across 80+ countries with mix of API’s and FDF’s More than Market Presence aon 80+ countries 53% Top quartile contributes 60% Total Revenue . 33%9 30% m API m FDF 300+ Regulatory Approvals 14% for API & Formulations Domestic Regulated Semi Regulated Working wit
Slide 15: Presence across all segments- An Integrated Player
Presence across all segments- An Integrated Player API, Finished Dosage Formulations (FDF) and Herbal with widespread market across geographies = API Manufacturer with 22+ Active Molecules. The range of APIs includes Anti-Diabetic, Anti-Histamine, Anti Inflammatory, Diuretic, Acne Treatment, Antipsy
Slide 16: Product Portfolio
Product Portfolio Antidiabetic 62% Antihistamine 21% Analgesics and antipyretics 48% Anti-inflammatory 4% Antibacterial 15% Diuretic 2% Cardiology 8% Acne treatment 1% Antidiabetics 6% Antimicrobial 4% Antipsychotic 1% Beta-lactams 3% Antihistamines 3% Gastroenterology 3% Erectile Dysfunction 2% Ant
Slide 17: Industry
Slide 18: Pharma Industry
Pharma Industry Global While the global pharmaceutical manufacturing market has reached $402 billion in 2020, the US and European markets alone will be worth $635 and $315 billion in sales by 2024, respectively. Global market is expected to grow at a compound annual growth rate (CAGR) of 11.34% from
Slide 19: Pharma Industry
Pharma Industry Growth Trend in the overall Low Labour Cost helps to reduce contribution of the pharma industry. cost of production and increase margins. Government Support under the Estimated Opportunity Aatmnirbhar Bharat government is taking all with 1.27 tr USD revenue the efforts to support Ind
Slide 20: Integrated Play
INTEGRATED PLAY
Slide 21: Investing in Bal Pharma: A play on integration and diversified mix
Investing in Bal Pharma: A play on integration and diversified product-client mix Bal Pharma well poised to deliver sustainable growth over long term ae An Integrated Player with well rates Export Markets to Reais L(-)———=(-)=! Domestic markets to Colac] Lay an) diversified product portfolio remain
Slide 22: Integrated play- Diversified product & Geographic mix
Integrated play- Diversified product & Geographic mix Segmental Mix Therapeutical Geographical Mix Mix Intermediates = 22+ Therapeutic areas =" Presence across 80+ ¢ Well diversified customer - : countries mix. Pe = One of the large player in Anti Diabetic Therapeutic =" Domestic operations are * St
Slide 23: Healthy Order Book & Strong Product Pipeline
Healthy Order Book & Strong Product Pipeline API (including Intermediates) Formulations (Finished Dosages) Order book of Rs. 370 Mn in API to be Order book of Rs. 270 Mn in FDF to be executed in executed in next months including both next months including both domestic and exports domestic and expor
Slide 24: Export Markets — a key driver of our current offerings
Export Markets — a key driver of our current offerings Company exports more than 22 API’s Company exports API’s to 80+ countries API exports form around ~ 74% in API’s Revenue API ~55% Competitive Pricing along with qualitative standards has led to repetitive orders from of Export Revenue Major glob
Slide 25: Domestic formulation operations: Vibrant, Glyduz, Institutional, Lifezen
PAN India Operations 246+ Field Force; 2800+ Stockists ; 41,300+ Doctor Reach Vibrant Multispecialty Nutritional supplements; Anti Allergic, Anti- Fungal, Gastro, Gynecological Presence in 8 states Glyduz and Diabetes and 127+ Field Force; 338 + Stockists; 12,000+ Doctor Reach Y=] ASI RU KS Cardiolo
Slide 26: Snapshot of Major Domestic Formulation Division
Snapshot of Major Domestic Formulation Division #8 |) Ertere Coated Panopez3e Socum 6 STONEX Capsules ..:|| | Aziwin-500 afafas sco Vibrant “Ebastine Tablets IP 20 mg O@-IPqy Ketoconazole Cream Ketovate’ cream Ebal-20 BE, creme |; 6X 5X 10 Tablets ts 10x10 Tablets i Teneligliptin Tablets 20 mg “Teln
Slide 27: Pharmaceutical Production Linked Incentive (PLI) Scheme
Pharmaceutical Production Linked Incentive (PLI) Scheme Sector Benefits How it will benefit BAL Pharma Objective: BAL pharma has received approval under the PLI scheme and placed under The objective of the scheme is to enhance India’s manufacturing capabilities by ‘Category C’ of the said scheme inc
Slide 28: Financial Overview
FINANCIAL OVERVIEW
Slide 29: Yearly Financial Highlights
Yearly Financial Highlights Revenue 3,000 2,803 API /Formulation 2,493 me, 2,500 2,231 —_ 60% 57% = 57% 0 ork 50% go «43% % TE 39, 79 1,500 40% 1,000 oe 9 20% 500 10% . 0% FY19.-FY20.—sFY21_~—séFY22 FYI9 FY200— F211 FY22 mw API Formulations Export/Domestic 70% 62% 62% 65% q i I i FY19 FY20 FY21 FY22
Slide 30: Key Result Highlights
Key Result Highlights Revenue API/Formulations 2,804 . 57% 2,493 12% mm 53% 7% == ) / nh aay |. FY21 FY22 FY 21 FY22 mw API Formulations Domestic/Export 65% 70% 35% 3004 a FY 21 FY 22 # Domestic Export